TOT BIOPHARM International Company Limited

Equities

1875

HK0000545266

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. 04:08:03 2024-03-28 am EDT 5-day change 1st Jan Change
1.65 HKD +8.55% Intraday chart for TOT BIOPHARM International Company Limited +6.45% -16.24%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
TOT BIOPHARM International Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
TOT Biopharm's Loss Narrows in January-September Period MT
TOT Biopharm's Loss Narrows in H1 MT
TOT BIOPHARM International Company Limited Announces Directorate and Committee Changes CI
TOT BIOPHARM International Company Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
TOT BIOPHARM's Q1 Loss Widens Despite Higher Revenue MT
TOT BIOPHARM International Company Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
TOT Biopharm Terminates Phase 3 Trial of Breast Cancer Drug; Shares Fall 5% MT
TOT BIOPHARM International Company Limited Announces Termination of Phase III Clinical Trial Study and Development of Taa013 CI
TOT BIOPHARM’s Production Base for Antibody Drug Receives Good Manufacturing Report from Europe MT
TOT BIOPHARM International Company Limited Announces Change of Address of Registered Office CI
TOT Biopharm International Logs Reduction in H1 Net Loss; Shares Climb 3% MT
TOT BIOPHARM International Company Limited Reports Earnings Results for the Half Year Ended June 30, 2022 CI
TOT BIOPHARM International Company Limited announced that it expects to receive HKD 110 million in funding from Center Laboratories, Inc. CI
TOT Biopharm Narrows Loss on Lower Selling, R&D Expenses in 2021 MT
TOT BIOPHARM International Company Limited Reports Earnings Results for the Full Year Ended December 31, 2021 CI
TOT BIOPHARM International Company Limited Announces Change of Directors and Change of Composition of Board Committees CI
China Approves New Indications for TOT Biopharm's Cancer Drug MT
TOT BIOPHARM International Company Limited Announces Change of Joint Company Secretary and Finance Personnel CI
TOT Biopharm International Unit Grants Kexing License to Commercialize Cancer Drug Overseas MT
TOT Biopharm Arm Engages MCC Unit to Construct Global R&D Center in Chinese Province MT
TOT Biopharm Sells 1 Million Shares in Lumosa Therapeutics to Center Laboratories MT
TOT BIOPHARM International Company Limited Announces NMPA Granted Marketing Approval for Pusintin in China CI
TOT Biopharm's Lung Cance Drug Bags Marketing Approval in China; Shares Rally 5% MT
TOT Biopharm International Forms Pharma Sales JV With China Resources Pharmaceutical MT
Chart TOT BIOPHARM International Company Limited
More charts
TOT BIOPHARM International Company Limited is a company mainly engaged in the development and commercialization of oncology drugs and therapies. The Company has a portfolio of oncology drug candidates, which include monoclonal antibodies (mAbs), antibody drug conjugates (ADCs), oncolytic virus products and specialty oncology drugs such as liposome drugs.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.524 CNY
Average target price
3.486 CNY
Spread / Average Target
+128.79%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock TOT BIOPHARM International Company Limited - Hong Kong S.E.
  4. News TOT BIOPHARM International Company Limited
  5. TOT Biopharm International Unit Grants Kexing License to Commercialize Cancer Drug Overseas